HAS-BLED Score for Major Bleeding Risk

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
has bled score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–1
  • Moderate Risk2–2
  • High Risk3–9
Direct Clinical Answer

The HAS-BLED Score for Major Bleeding Risk calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include hypertension. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Estimates 1-year risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care. Used with CHA2DS2-VASc score to balance stroke vs bleeding risk.

Clinical Indication

The HAS-BLED Score for Major Bleeding Risk is indicated for bedside clinical practice to support Estimates 1-year risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care. Used with CHA2DS2-VASc score to balance stroke vs bleeding risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Do not use HAS-BLED alone to withhold anticoagulation.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

HAS-BLED Score = Hypertension (1) + Abnormal renal function (1) + Abnormal liver function (1) + Stroke (1) + Bleeding (1) + Labile INR (1) + Elderly (1) + Drugs (1) + Alcohol (1)

Input Parameters

NameTypeRequiredDescription
hypertensionstringYesHypertension (uncontrolled, systolic blood pressure >160 mmHg)
abnormal_renal_functionstringYesAbnormal renal function (dialysis, renal transplant, or serum creatinine >2.26 mg/dL or >200 μmol/L)
abnormal_liver_functionstringYesAbnormal liver function (cirrhosis or bilirubin >2x normal with AST/ALT/AP >3x normal)
stroke_historystringYesPrevious stroke (ischemic or hemorrhagic)
bleeding_historystringYesPrior major bleeding or predisposition to bleeding (anemia, bleeding diathesis, etc.)
labile_inrstringYesLabile INR (unstable/high INRs, time in therapeutic range <60%)
elderlystringYesElderly (age >65 years)
drugsstringYesDrugs predisposing to bleeding (antiplatelet agents, NSAIDs)
alcoholstringYesAlcohol use (≥8 drinks per week)

Score Interpretation & Guidance

RangeStageDescription
0–1Low RiskLow bleeding risk
2–2Moderate RiskModerate bleeding risk
3–9High RiskHigh bleeding risk

Evidence-Based References (EBM)

  • Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134.DOI: 10.1378/chest.10-0134
  • Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024.DOI: 10.1016/j.jacc.2010.09.024
  • Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012 Aug 28;60(9):861-7. doi: 10.1016/j.jacc.2012.06.019.DOI: 10.1016/j.jacc.2012.06.019

Related calculators